trabectedin

Also known as ecteinascidin 743, ET-743, Yondelis®, Ect 743, ET743, Ecteinascidin, Ecteinascidin 743

Trabectedin, sold under the brand name Yondelis, is an antitumor chemotherapy medication for the treatment of advanced soft-tissue sarcoma and ovarian cancer.

Research

1,148 papers

Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma.The New England journal of medicine · 2024
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.The Lancet. Oncology · 2022
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016
Trabectedin in Cancers: Mechanisms and Clinical Applications.Current pharmaceutical design · 2022
Focus on Trabectedin in Ovarian Cancer: What Do We Still Need to Know?Drug design, development and therapy · 2024

via PubMed

~9 min read

Article

11 sections

Contents

Discovery and production
Approvals and indications
Soft tissue sarcoma
Ovarian cancer and other
Structure
Biosynthesis
Total synthesis
Mechanism of action
Society and culture
Legal status
References

Trabectedin, sold under the brand name Yondelis, is an antitumor chemotherapy medication for the treatment of advanced soft-tissue sarcoma and ovarian cancer.

The most common adverse reactions include nausea, fatigue, vomiting, constipation, decreased appetite, diarrhea, peripheral edema, dyspnea, and headache.